Skip to main content

Advertisement

Table 1 Sociodemographic, clinical, and biomarker variables in the final analysis set (n = 115) and in the respective comparison group (max. n = 956; actual group size for each variable is the maximal N available for the comparison group)

From: Incremental value of biomarker combinations to predict progression of mild cognitive impairment to Alzheimer’s dementia

Variable Final analysis sample (n =115) MCI-stable + MCI-AD Comparison group (n = 956) P value
Group size (n) All other MCI with data available
Age 65.7 ± 9.0 956 67.1 ± 8.6 ns
Sex (male = 1) 1.4 ± 0.5 956 1.5 ± 0.5 ns
education 9.5 ± 1.9 956 9.5 ± 1.9 ns
MMSE 27.0 ± 2.1 956 27.2 ± 2.2 ns
MADRS 7.4 ± 5.6 908 7.8 ± 6.2 ns
B-ADL 2.5 ± 1.5 903 2.3 ± 1.4 ns
CDR-sb 1.8 ± 1.1 956 1.5 ± 1.0 0.01
CERAD-DR-WL 4.8 ± 2.3 956 5.0 ± 2.3 ns
Hippocampal volume 4450 ± 672 368 4511 ± 653 ns
Aβ42 749 ± 300 292 751 ± 353 ns
Aβ40 9654 ± 2732 268 9684 ± 3030 ns
Aβ ratio 0.08 ± 0.03 266 0.08 ± 0.04 ns
Total tau 411 ± 251 284 446 ± 304 ns
Phosphorylated tau 61 ± 30 289 67 ± 36 ns
  1. Data are given as mean ± standard deviation
  2. There is no significant difference between the groups with the exception of CDR-sb which is not clinically relevant
  3. P values were uncorrected for multiple comparisons
  4. Aβ40 amyloid-beta1–40, Aβ42 amyloid-beta1–42, AD Alzheimer’s disease, B-ADL Bayer activities of daily living, CDR-sb Clinical Dementia Rating–sum-of-boxes, CERAD-DR-WL Consortium to Establish a Registry of Dementia–delayed recall word list, MADRS Montgomery-Asberg Depression Rating Scale, MCI cognitive impairment, MMSE Mini-Mental State Examination, ns not significant